ClinicalTrials.Veeva

Menu

Diabetes Risk Communication Tool Evaluation

N

National University of Singapore

Status

Completed

Conditions

Type 2 Diabetes

Treatments

Behavioral: T2D Risk Communication Tool: Relative Risk
Behavioral: T2D Risk Communication Tool: Metabolic Age
Behavioral: T2D Risk Communication Tool: Traffic Light

Study type

Interventional

Funder types

Other

Identifiers

NCT05427890
NUS-IRB-2021-633 (Other Identifier)
OF-LCG-RiskComm

Details and patient eligibility

About

Prevention for Type 2 Diabetes (T2D)has been vast but with limited success. While Singaporeans have high knowledge about T2D, its symptoms, and risk factors, healthy practices are still sub-optimal. Upon a qualitative investigation, it was found that there is little to no urgency to engage in T2D preventative behaviour due to to the low perceived threat, and high costs from required lifestyle changes relative to the benefits. Hence, this project targets to communicate the risk of diabetes in a more salient and effective way to improve the intention of preventative behaviour by targeting the constructs of Protection Motivation Theory (PMT) and increasing the threat and coping appraisals. The current available diabetes risk assessment tool's result page provides a binary output: "Higher vs Lower" Risk of being pre-diabetic. This aligns with the usual care practiced in clinics currently; patients are told if they are pre-diabetic or not. It does not provide any personalized or relevant tips on how to reduce risk. Hence, there was a demonstrated need to develop risk assessment tools that increase threat appraisal and communicate T2D risk in a more salient way to motivate the intention of behaviour change. The investigators developed two tools: Relative Risk, and Metabolic Age. The Relative Risk prototype demonstrates the user's relative risk on a scale of 1 to 10, in comparison to someone of the same age and sex. The number 1-10 represents their position in the percentile distribution of their risk scores. The Metabolic Age is identified by matching the risk score's percentile position to percentile of the incidence of T2D. The median age of the people in that percentile is reflected as the metabolic age. The primary objectives of this study is to evaluate which of these risk presentations (Usual care, relative risk, or metabolic age) evoke (i) effective cognitive and emotional responses to risk results and (2) motivation for the intention of behaviour change. The secondary objective is to provide empirical evidence for using PMT constructs in intervention development. The hypothesis is that those who are exposed to the Metabolic Age risk assessment and communication tool will have the most effective cognitive and emotional response, and the highest intention of engaging in behaviour change, followed by those exposed to relative risk, and then standard of care.

Enrollment

460 patients

Sex

All

Ages

30 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Aged 30-60 years;
  • Singapore citizen, or permanent resident
  • Able to read and understand English,
  • Have had a health screening with blood pressure, triglycerides, and HbA1C done within the last 3 months
  • At least one risk factor for Type 2 Diabetes (BMI ≥ 23 kg/m2, blood pressure ≥130/85 mmHg or receiving therapy for hypertension, triglycerides ≥1.7mmol/L or HbA1c ≥5.7%)

Exclusion criteria

  • Diagnosis of any event of cardiovascular disease, kidney issues, or type 2 diabetes

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

460 participants in 3 patient groups

Usual Care
Active Comparator group
Treatment:
Behavioral: T2D Risk Communication Tool: Traffic Light
Relative Risk
Experimental group
Treatment:
Behavioral: T2D Risk Communication Tool: Relative Risk
Metabolic Age
Experimental group
Treatment:
Behavioral: T2D Risk Communication Tool: Metabolic Age

Trial contacts and locations

1

Loading...

Central trial contact

Huso Yi, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems